Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Diamyd Medical

9,88 SEK

-0,20 %

Mindre end 1K følgere

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-0,20 %
-6,08 %
-16,84 %
0,00 %
-39,62 %
-32,48 %
-36,30 %
-67,52 %
+229,04 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Læs mere
Markedsværdi
1,36 mia. SEK
Aktieomsætning
2,26 mio. SEK
Omsætning
130 t
EBIT %
-140.953,85 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
28.1
2026

Delårsrapport Q1'26

25.3
2026

Delårsrapport Q2'26

24.6
2026

Delårsrapport Q3'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsefor 12 timer siden

Bulletin from Annual General Meeting of Diamyd Medical AB

Diamyd Medical
Selskabsmeddelelse2.12.2025, 09.55

Diamyd Medical AB: Annual Report 2024/2025

Diamyd Medical
Pressemeddelelse1.12.2025, 06.41

BioStock: Lif's sustainability conference 2025 with a focus on transition, competitiveness and sustainable production

Diamyd Medical

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse14.11.2025, 07.45

Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026

Diamyd Medical
Selskabsmeddelelse13.11.2025, 07.28

Diamyd Medical AB: Information about the Annual Report 2024/2025

Diamyd Medical
Selskabsmeddelelse12.11.2025, 11.45

Diamyd Medical AB: Diamyd Medical marks World Diabetes Day with expert panel on the future of Type 1 Diabetes treatment

Diamyd Medical
Pressemeddelelse10.10.2025, 10.16

BioStock: Screening - a potential game changer for type 1 diabetes

Diamyd Medical
Pressemeddelelse9.10.2025, 05.27

DNB Carnegie Access: Diamyd Medical: Solid finish to the fiscal year

Diamyd Medical
Selskabsmeddelelse8.10.2025, 06.15

Diamyd Medical AB: Year-End Report 24/25

Diamyd Medical
Selskabsmeddelelse3.10.2025, 12.40

Diamyd Medical AB: Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes

Diamyd Medical
Pressemeddelelse25.9.2025, 09.36

BioStock: Video from Diamyd Medical's presentation at BioStock Investing in Life Science – From Seed to Success

Diamyd Medical
Selskabsmeddelelse11.9.2025, 08.00

Diamyd Medical AB: New analysis to be presented at EASD supports potential of Diamyd[®] to delay the progression of Stage 3 Type 1 Diabetes

Diamyd Medical
Selskabsmeddelelse10.9.2025, 07.00

Diamyd Medical AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes

Diamyd Medical
Selskabsmeddelelse5.9.2025, 11.00

Diamyd Medical AB: ASSET partnership, coordinated by Diamyd Medical, organizes 2[nd] annual Type 1 Diabetes screening conference

Diamyd Medical
Pressemeddelelse3.9.2025, 04.18

DNB Carnegie Access: Diamyd Medical: DNB Carnegie’s Micro & Small Cap Day 2025 – highlights

Diamyd Medical
Selskabsmeddelelse22.7.2025, 14.00

Diamyd Medical AB: Diamyd Medical releases the full video recording from a panel discussion at the ADA meeting in June

Diamyd Medical
Pressemeddelelse1.7.2025, 09.44

DNB Carnegie Access: Diamyd Medical: Progress towards key catalyst in March 2026 – Q3 review

Diamyd Medical
Pressemeddelelse1.7.2025, 08.00

DNB Carnegie Access: Diamyd Medical: Intervju - Närmar sig viktiga studiedata

Diamyd Medical
Selskabsmeddelelse25.6.2025, 06.15

Diamyd Medical AB: Quarterly Report 3 24/25

Diamyd Medical
Selskabsmeddelelse16.6.2025, 13.05

Diamyd Medical AB: Diamyd Medical to participate in two key US diabetes events

Diamyd Medical
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.